QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer

NCT07186868 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Cervical Cancer
Metastatic Cervical Cancer

Interventions

BIOLOGICAL: Iparomlimab and Tuvonralimab (QL1706) + Nab-Paclitaxelwith or without Bevacizumab

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences